Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095443 | 0.80 | ALDH1A1 (0.43) | CYP3A4MRGPRX4TDP1ALDH1A1MEN1 | |
| SCHEMBL15475846 | 0.77 | CYP3A4 (0.36) | CYP3A4MAPK1FABP3MRGPRX4TDP1 | |
| SCHEMBL28202875 | 0.77 | CYP3A4 (0.43) | CYP3A4MAPK1ALDH1A1AHR | |
| SCHEMBL11703762 | 0.74 | ALDH1A1 (0.33) | CYP3A4MAPK1TDP1ALDH1A1MEN1 | |
| SCHEMBL9486392 | 0.72 | HTR2A (0.33) | CYP3A4MAPK1MRGPRX4GPR84 | |
| SCHEMBL11283671 | 0.72 | CYP3A4 (0.43) | CYP3A4MAPK1FABP3MRGPRX4TDP1 | |
| SCHEMBL27278573 | 0.72 | CYP3A4 (0.48) | CYP3A4MAPK1TDP1ALDH1A1AHR | |
| SCHEMBL8665449 | 0.71 | TDP1 (0.43) | CYP3A4MRGPRX4TDP1ALDH1A1 | |
| SCHEMBL4593314 | 0.71 | TTR (0.49) | TDP1KMT2A | |
| SCHEMBL54889 | 0.70 | LMNA (0.47) | TDP1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059981-A | Preparation method of Olaparib | 山东新时代药业有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118812361-A | Method for preparing carboxylic acid aryl ester by internal olefin migration hydrogen esterification reaction | 常州大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-117417253-A | Method for preparing phenyl alkyl acid ester by alkyl olefin | 常州大学 | 2024-01-19 | — | — | CN | disclosed |
| US-11591225-B2 | Method for producing carbon monoxide | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-02-28 | — | — | US | disclosed |
| US-20210188650-A1 | METHOD FOR PRODUCING CARBON MONOXIDE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-06-24 | — | — | US | disclosed |
| WO-2021065893-A1 | TETRALIN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | 国立大学法人 筑波大学 | 2021-04-08 | — | — | WO | disclosed |
| EP-3740465-A1 | METHOD FOR PRODUCING CARBON MONOXIDE | Commissariat à l'énergie atomique et aux énergies alternatives (CEA) (FR) | 2020-11-25 | — | — | EP | disclosed |
| EP-3699167-A1 | PROCESS FOR PREPARING METHYL 1-BENZOSUBERONE-7-CARBOXYLATE | Sanofi (FR) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019141634-A1 | METHOD FOR PRODUCING CARBON MONOXIDE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-07-25 | — | — | WO | disclosed |
| US-8883777-B2 | Compositions controlling pH range of release and/or release rate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1351992-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | Ramot at Tel Aviv University Ltd. (IL) | 2003-10-15 | — | — | EP | disclosed |
| US-20030130268-A1 | Mixture containing water soluble polymer and surfactant; antiinflammatory agents, antiulcer agents, Crohn's disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| WO-2002055543-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | UNIV RAMOT (IL) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591225-B2 | Method for producing carbon monoxide | ALDOA, CYP4A11, ADH1A | CYP3A4 18/4885MAPK1 2148/4885FABP3 988/4885 |
| US-20210188650-A1 | METHOD FOR PRODUCING CARBON MONOXIDE | ALDOA, CYP4A11, ADH1A | CYP3A4 18/4885MAPK1 2148/4885FABP3 988/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP3A4 1683/4885MAPK1 1392/4885FABP3 349/4885 |
| US-20030130268-A1 | Mixture containing water soluble polymer and surfactant; antiinflammatory agents, antiulcer agents, Crohn's disease | SI, ABCB11, NOD2 | CYP3A4 1477/4885MAPK1 1584/4885FABP3 4150/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP3A4 1734/4885MAPK1 2105/4885FABP3 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.